Quinolone derivative or salt thereof
AssigneeAstellas Pharma Inc.
InventorsSusumu Watanuki, Yuji Koga, Hiroyuki Moritomo, Issei Tsukamoto, Daisuke Kaga, Takao Okuda, Fukushi Hirayama, Yumiko Moritani, Jun Takasaki
Life of this patent
Estimating the term…
Abstract
A platelet aggregation inhibitor comprising a quinolone derivative or a pharmaceutically acceptable salt thereof as an active ingredient, and a novel quinolone derivative or a pharmaceutically acceptable salt thereof useful as a platelet aggregation inhibitor.
Claims21
A platelet aggregation inhibitor comprising a quinolone derivative represented by the formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient:
- [the symbols in the formula have the following meanings:
- X:
- C—R7 or N;
- Y:
- C—R6 or N;
- R11:
- —H, a lower alkyl which may be substituted, or an amino which may be substituted with a lower alkyl which may be substituted;
- R12:
- —H, or a lower alkyl or an aryl which respectively may be substituted, provided that R11 and R12 together with the adjacent nitrogen may form a cyclic amino which may be substituted;
- R2:
- a lower alkyl, a cycloalkyl, an aryl or a hetero ring, which respectively may be substituted;
- R3:
- a halogen, a lower alkyl or —O-lower alkyl;
- R4:
- a cycloalkyl or a non-aromatic hetero ring, which respectively may be substituted, or a lower alkyl substituted with a cycloalkyl;
- provided that when R4 represents a non-aromatic hetero ring which may be substituted, a carbon atom constituting the ring binds to the adjacent NH;
- R5:
- —H, a halogen, cyano, nitro, a lower alkyl, a halogeno-lower alkyl, a cycloalkyl, an aryl, a hetero ring, —O-lower alkyl, —OH, —NHCO-lower alkyl, —N(lower alkyl)CO-lower alkyl, an amino which may be substituted with a lower alkyl, or a cyclic amino which may be substituted;
- R6:
- —H, a halogen, a lower alkyl or a halogeno-lower alkyl;
- R7:
- —H, a halogen, a lower alkyl or a halogeno-(lower alkyl);
- provided that when Y represents C—R6, R2 and R6 together may form a lower alkylene or a lower alkenylene.
A quinolone derivative represented by the formula (I-a) or a pharmaceutically acceptable salt thereof:
- [the symbols in the formula have the following meanings:
- X:
- C—R7 or N;
- Y:
- C—R6 or N;
- R11:
- —H, a lower alkyl which may be substituted, or an amino which may be substituted with a lower alkyl which may be substituted;
- R12:
- —H, or a lower alkyl or an aryl, which respectively may be substituted, provided that R11 and R12 together with the adjacent nitrogen may form a cyclic amino which may be substituted;
- R2:
- a lower alkyl, a cycloalkyl, an aryl or a hetero ring, which respectively may be substituted;
- R3:
- a halogen, a lower alkyl or —O-lower alkyl;
- R4:
- a cycloalkyl or a non-aromatic hetero ring, which respectively may be substituted, or a lower alkyl substituted with a cycloalkyl;
- provided that wherein R4 represents a non-aromatic hetero ring which may be substituted, a carbon atom constituting the ring binds to the adjacent NH;
- R5:
- —H, a halogen, cyano, nitro, a lower alkyl, a halogeno-lower alkyl, a cycloalkyl, an aryl, a hetero ring, —O-lower alkyl, —OH, —NHCO-lower alkyl, —N(lower alkyl)CO-lower alkyl, an amino which may be substituted with a lower alkyl, or a cyclic amino which may be substituted;
- R6:
- —H, a halogen, a lower alkyl or a halogeno-lower alkyl;
- R7:
- —H, a halogen, a lower alkyl or a halogeno-(lower alkyl);
- provided that when Y represents C—R6, R2 and R6 together may form a lower alkylene or a lower alkenylene and provided that 7-(cyclohexylamino)-1-ethyl-6-fluoro-4-oxo-1,4-dihydroquinoline-3-carbohydrazide is excluded.
Dependencies are inferred from the claim text.